Disturbing asthma statistics reflect suboptimal management.
Grum
C M
CM
University of Michigan, USA.
D000318:Adrenergic beta-Agonists / Q000627:therapeutic use; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy*; D019819:Budesonide; D006801:Humans; D007167:Immunotherapy; D007211:Indoles; D020024:Leukotriene Antagonists; D048448:Phenylcarbamates; D011282:Pregnenediones / Q000627:therapeutic use; D013449:Sulfonamides; D013726:Terbutaline / Q000627:therapeutic use; D014105:Tosyl Compounds / Q000009:adverse effects / Q000627:therapeutic use; D014481:United States
D000318:Adrenergic beta-Agonists; D018927:Anti-Asthmatic Agents; D000893:Anti-Inflammatory Agents; D007211:Indoles; D020024:Leukotriene Antagonists; D048448:Phenylcarbamates; D011282:Pregnenediones; D013449:Sulfonamides; D014105:Tosyl Compounds; D019819:Budesonide; D013726:Terbutaline; C062735:zafirlukast